Lercanidipine in Hypertension

References

• [ADA] American Diabetes AssociationArauz-PachecoCParrottMAHypertension management in adults with diabetesDiabetes Care200427Suppl 1S65714693929
   PubMedGoogle Scholar
• ALLHAT Officers and CoordinatorsMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• AngelicoPGuarneriLLeonardiAVascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissuesJ Pharm Pharmacol1999517091410454048
   PubMed Web of Science ®Google Scholar
• ArandaPArandaFJBianchiJLTherapeutic efficacy and tolerability of lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensivesJ Hypertens200018Suppl 2S152
   Google Scholar
• BangLMChapmanTMGoaKLLercanidipine: a review of its efficacy in the management of hypertensionDrugs20036324497214609358
   PubMed Web of Science ®Google Scholar
• BarbagalloMBarbagalloSGEfficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertensionAging (Milano)200012375911126524
   PubMedGoogle Scholar
• BarriosVCalderonANavarroALercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG studyJ Hypertens2004a22Suppl 2S2589
   Google Scholar
• BarriosVCalderonANavarroALercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The Laura studyJ Hypertens2004b22Suppl 2S235
   Google Scholar
• BarriosVNavarroAEsterasAAntihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de SeguridadBlood Press2002119510012035878
   PubMed Web of Science ®Google Scholar
• BellostaSBerniniFLipophilic calcium antagonists in antiatherosclerotic therapyCurr Atheroscler Rep20002768111122728
   PubMedGoogle Scholar
• BorghiCPrandinMGDormiAImproved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trialBlood Press2003Suppl 11421
   Google Scholar
• BrownMJPalmerCRCastaigneAMorbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)Lancet20003563667210972368
   PubMed Web of Science ®Google Scholar
• CalvoCHermidaRCNavarroATreatment of elderly hypertensive patients. preliminary results from the zanycal study [abstract]Am J Hypertens200215110A
   Google Scholar
• CavalliniATerziGEffects of antihypertensive therapy with lercanidipine and verapamil in cardiac electrical activity in patients with hypertension: a randomised, double-blind pilot studyCurr Ther Res20006147787
   Web of Science ®Google Scholar
• CesaroneMRIncandelaLLeddaAPressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertensionAngiology200051S536310959511
   PubMed Web of Science ®Google Scholar
• CherubiniAFabrisFFerrariEComparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) studyArch Gerontol Geriatr2003372031214511846
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034212065214656957
   PubMed Web of Science ®Google Scholar
• CifkovaRErdineSFagardRPractice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelinesJ Hypertens20032117798614508180
   PubMedGoogle Scholar
• CleophasTJvan OuwerkerkBMvan derMJDiabetics with hypertension not controlled with ACE inhibitors: alternate therapiesAngiology2001524697511515986
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRMacMahonSBlood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextLancet1990335827381969567
   PubMed Web of Science ®Google Scholar
• Dalla VestraMPozzaGMoscaAEffect of lercanidpine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina)Diab Nutr Metab20041725966
   PubMedGoogle Scholar
• De GiorgioLAOrlandiniFMalasomaPDouble-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertensionCurr Ther Res19996051120
   Web of Science ®Google Scholar
• DigiesiVFiorilloCCosmiLReactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonistsClin Ter2000151151810822876
   PubMedGoogle Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• FogariRMalamaniGDZoppiAComparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutanous interstitial pressure in hypertensive patients: a double-blind, randomised, parallel-group studyCurr Ther Res Clin Exp20006185062
   Web of Science ®Google Scholar
• FogariRMugelliniACorradiLEfficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patientsJ Hypertens200018Suppl 2s65
   PubMedGoogle Scholar
• FogariRMugelliniAZoppiADifferential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertensionAm J Hypertens200316596912850395
   PubMed Web of Science ®Google Scholar
• GrassiGSeravalleGTurriCShort-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertensionHypertension2003415586212623959
   PubMed Web of Science ®Google Scholar
• GuarneriLAngelicoPIbbaMPharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipineArzneimittelforschung19964615248821512
   PubMed Web of Science ®Google Scholar
• GuillenVFGAbellanJLlisterriJLEfficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study groupAm J Hypertens200316115A
   Web of Science ®Google Scholar
• HanssonLHednerTLund-JohansenPRandomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyLancet20003563596510972367
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHEkbomTRandomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 studyLancet19993541751610577635
   PubMed Web of Science ®Google Scholar
• HerbetteLGVecchiarelliMSartaniALercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic propertiesBlood Press Suppl1998210179850437
   PubMedGoogle Scholar
• HollenbergNKObservations on the safety of lercanidipine: adverse event data from placebo-controlled trialsAm J Hypertens20021558A59A11824862
   PubMed Web of Science ®Google Scholar
• IncandelaLBelcaroGCesaroneMROxygen-free radical decrease in hypertensive patients treated with lercanidipineInt Angiol2001201364011533521
   PubMed Web of Science ®Google Scholar
• JamesIGVJonesADaviesPA randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertensionJ Hum Hypertens2002166051012149668
   PubMed Web of Science ®Google Scholar
• KostisJBTreatment of hypertension in older patients: an updated look at the role of calcium antagonistsAm J Geriatr Cardiol2003123192712963858
   PubMedGoogle Scholar
• LeonettiGThe safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipineHigh Blood Press1999892101
   Google Scholar
• LeonettiGMagnaniBPessinaACTolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensivesAm J Hypertens2002159324012441211
   PubMed Web of Science ®Google Scholar
• Lund-JohansenPStrandenEHelbergSQuantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipineJ Hypertens20032110031012714876
   PubMed Web of Science ®Google Scholar
• LuqueMRuilopeLMTamargoJDrug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN studyAm J Hypertens200420Suppl 4S163
   Google Scholar
• MacchiaruloCPieriRMitoloDCAntihypertensive effects of 6 calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordingsCurr Ther Res20016223653
   Web of Science ®Google Scholar
• MallionJMAllaertFAScart-GresCVariations in the frequency of lower limb oedema in patients recieving lercanidipine in adjunction to their antihypertensive treatmentJ Hypertens200422Suppl 2S269
   Google Scholar
• MartellNLopez-EadyMDCastroPModifications of the pulse pressure in elderly hypertensives treated with lercanidipineJ Hypertens200422Suppl 2S121
   PubMedGoogle Scholar
• MarxALichtenthalAMilbredtCEffect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseasesJ Hypertens200422Suppl 2S236
   Google Scholar
• MesserliFHCalcium antagonists in hypertension: from hemodynamics to outcomesAm J Hypertens20021594S97S12121012
   PubMed Web of Science ®Google Scholar
• Millar-CraigMShaffuBGreenoughALercanidipine vs lacidipine in isolated systolic hypertensionJ Hum Hypertens20031779980614578921
   PubMed Web of Science ®Google Scholar
• MoriscoCTrimarcoBEfficacy and tolerability of lercanidipine in comparison to and in combination with atenol in patients with mild to moderate hypertension in a double-bind controlled studyJ Cardiovasc Pharmacol199729S2630
   Google Scholar
• MoteroJMarquesEEugenioJMComparative study of the antihypertensive efficacy of lercanidipine in the treatment of mild to moderate high blood pressure in patients under and over 65 years old [abstract]J Hypertens200220Suppl 4S162
   Google Scholar
• NinciMAMaglioccaRMallianiAEfficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind studyJ Cardiovasc Pharmacol199729S404
   Google Scholar
• NotarbartoloARengoFScafidiVLong-term effects of lercanidipine on the lipoprotein and apolipopprotein profile of patients with mild-to-moderate essential hypertensionCurr Ther Res19996022836
   Web of Science ®Google Scholar
• OmboniSZanchettiAOn behalf of the Multicenter Study InvestigatorsAntihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurementsJ Hypertens199816183189869018
   PubMed Web of Science ®Google Scholar
• PedrinelliRDell'OmoGNutiMHeterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patientsJ Hypertens20032119697314508205
   PubMed Web of Science ®Google Scholar
• PolicicchioDMaglioccaRMallianiAEfficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow release nifedipineJ Cardiovasc Pharmacol199729S315
   Google Scholar
• PonceletPRibsteinJGoullardLEfficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE studyAnn Cardiol Angeiol (Paris)2004531233015291167
   PubMedGoogle Scholar
• RachmaniRLeviZZadokBSLosartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover studyClin Pharmacol Ther200272302712235451
   PubMed Web of Science ®Google Scholar
• RengoFRomisLActivity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertensionJ Cardiovasc Pharmacol199729S548
   Google Scholar
• RoblesNRCaneladaJAIglesiasMEvaluation of lercanidipine in the general practice settingAnn Med Interna2003202826
   Google Scholar
• RoblesNRPastorLManjonMLercanidipine in diabetic patients with renal failureNefrologia2004243384315455493
   PubMed Web of Science ®Google Scholar
• RoblesNROconJGomezCFLercanidipine in patients with chronic renal failure: The ZAFRA studyRen Fail200527738015717638
   PubMed Web of Science ®Google Scholar
• RomaJSobrinoJSoler-AmigoJTreatment with lercanidipine during six months in hypertensive elderly patients (more than sixty years)J Hypertens200420Suppl 4S391
   Google Scholar
• RomitoRPansiniMIPerticoneFComparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) StudyJ Clin Hypertens (Greenwich)200352495312939564
   PubMedGoogle Scholar
• SabbatiniMLeonardiATestaREffect of calcium antagonists on glomerular arterioles in spontaneously hypertensive ratsHypertension2000a35775910720594
   PubMed Web of Science ®Google Scholar
• SabbatiniMLeonardiATestaREffects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive ratsJ Cardiovasc Pharmacol200239394811743226
   PubMed Web of Science ®Google Scholar
• SabbatiniMVitaioliLBaldoniENephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive ratsJ Pharmacol Exp Ther2000b2949485410945845
   PubMed Web of Science ®Google Scholar
• SangiorgiGBPutignanoECalcaraLEfficacy and tolerability of lercanidipine vs captopril in patients with mild to moderate hypertension in a double controlled studyJ Cardiovasc Pharmacol199729Suppl 2s369
   Google Scholar
• SarafidisPLasaridisAHatzistavriLThe effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patientsRev Clin Pharmacol Pharmacokinet Int200418606
   Google Scholar
• SchwingerRHGSchmidt-MertensAThe new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effectsDtsch Med Wochenschr2002127Suppl 1s13
   Google Scholar
• SeravalleGStellaMLFogliaGTemporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension [abstract]J Hypertens200220S190
   Web of Science ®Google Scholar
• SironiGMontagnaEGretoLAntihypertensive effects of lercanidipine in experimental hypertensive rats and dogsArzneimittelforschung1996a46145528720303
   PubMed Web of Science ®Google Scholar
• SironiGMontagnaEGretoLHaemodynamic effects of lercanidipine in anaesthetized open-chest dogsArzneimittelforschung1996b46256618901145
   PubMed Web of Science ®Google Scholar
• StergiouGSSalgamiEVNew European, American and International guidelines for hypertension management: agreement and disagreementExpert Rev Cardiovasc Ther200423596815151482
   PubMedGoogle Scholar
• TaddeiSVirdisAGhiadoniLCalcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertensionHypertension200341950512642509
   PubMed Web of Science ®Google Scholar
• VersariDVirdisAGhiadoniLLercanidipine restores nitric oxide availability in the forearm of essential hypertensive patientsAm J Hypertens200415Part 242A
   Google Scholar
• VivianiGLLercanidipine in type II diabetic patients with mild to moderate arterial hypertensionJ Cardiovasc Pharmacol200240133912072586
   PubMed Web of Science ®Google Scholar
• WeirMRIncidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significanceJ Clin Hypertens (Greenwich)20035330514564133
   PubMedGoogle Scholar
• WirtzSHerzigSMolecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipineBr J Pharmacol20041422758415155536
   PubMed Web of Science ®Google Scholar
• [WHO] World Health Organization, International Society of Hypertension Writing Group2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens20032119839214597836
   PubMed Web of Science ®Google Scholar